Friday 6 November 2026 Export ARQT’s income statement to Excel — free account

Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 91.3% from fiscal 2024.

Revenue: +45.1%
EPS: +12.0%
Free cash flow: +1,171.9%
Total debt: +0.83%

Quarter to September 2026, against a year earlier

25.55 1.45 −5.37%

Follow ARQT

Alert me

Market cap: $3.4B
P/E: 112×
Fwd P/E: 81.2×
Dividend yield: —
F-score: 4/9
Altman Z: 6.98
Beneish M: −1.52
Dividend safety: n/a

Overview

Arcutis Biotherapeutics, Inc. (ARQT) P/B ratio

Alert me on P/B ratio

As of 6 November 2026, Arcutis Biotherapeutics, Inc. (ARQT) trades at a P/B ratio of 13.7×. Over the past ten years it has ranged from 0.0× (March 2020) to 25.2× (December 2025); the current reading is higher than 82% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/ARQT/pb-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Arcutis Biotherapeutics, Inc. P/B ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/ARQT/metrics/pb-ratio">Arcutis Biotherapeutics, Inc. (ARQT) P/B ratio — stockrow.com</a></p>

Period	P/B ratio	Change
FY2025	19.5×	82.32%
FY2024	10.7×	298.93%
FY2023	2.7×	(30.87%)
FY2022	3.9×	—

Period	P/B ratio	Change
Sep 2026	14.2×	(8.52%)
Jun 2026	15.5×	(3.46%)
Mar 2026	16.1×	(17.59%)
Dec 2025	19.5×	28.13%
13 more quarters	Free account

Against its own ten years

Low 0.0× High 25.2×

Ten-year median 5.0×

Current reading's percentile 85

Company	P/B ratio
TNGX Tango Therapeutics, Inc. compare	3.1×
LEGN Legend Biotech Corporation Sponsored ADR compare	3.4×
DFTX Definium Therapeutics, Inc. compare	3.7×
ABCL AbCellera Biologics Inc. compare	3.8×
DNTH Dianthus Therapeutics, Inc. compare	3.9×
RLAY Relay Therapeutics, Inc. compare	3.9×
IOVA Iovance Biotherapeutics, Inc. compare	4.3×
EWTX Edgewise Therapeutics, Inc. compare	9.4×
ARQT Arcutis Biotherapeutics, Inc.	14.6×
Biotechnology industry median	2.0×
Healthcare sector median	2.3×
Market median	1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

Arcutis Biotherapeutics, Inc. (ARQT) P/B ratio

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on ARQT

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on ARQT

Stockrow Weekly